Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
REPL
REPL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REPL News
UniQure to Seek FDA Approval for Huntington's Gene Therapy
2d ago
CNBC
UniQure to Seek Approval for Huntington's Gene Therapy
2d ago
Newsfilter
Replimune's Cancer Immunotherapy Shows Promising Early Data
Jun 01 2026
stocktwits
Replimune Receives FDA Support for BLA Resubmission
Jun 01 2026
NASDAQ.COM
Replimune Presents Final Data for RP2 Oncolytic Therapy
May 31 2026
Newsfilter
Replimune Reports Landmark Three-Year Survival Data
May 30 2026
NASDAQ.COM
Replimune Secures FDA Approval to Resubmit RP1 Application
May 30 2026
seekingalpha
Replimune Secures FDA Agreement, Shares Surge 80%
May 29 2026
stocktwits
Biotech Stocks Show Significant Pre-Market Activity
May 29 2026
NASDAQ.COM
Replimune Plans to Resubmit Melanoma Drug Application to FDA
May 29 2026
CNBC
Replimune Plans to Resubmit Melanoma Drug Application Following FDA Leadership Change
May 29 2026
Newsfilter
Replimune Plans to Resubmit RP1 Application After FDA Rejection
May 29 2026
seekingalpha
Replimune Aligns with FDA on RP1 Resubmission Pathway
May 29 2026
Newsfilter
Pomerantz LLP Investigates Replimune for Securities Fraud
May 21 2026
PRnewswire
Pomerantz LLP Investigates Replimune for Securities Fraud
May 19 2026
Globenewswire
Replimune Group Faces Securities Investigation
May 18 2026
Globenewswire
Show More News
